Lantern Pharma (LTRN) News Today $3.32 +0.15 (+4.73%) Closing price 04:00 PM EasternExtended Trading$3.33 +0.01 (+0.33%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Lantern Pharma (LTRN) Q1 2025 Earnings Transcript14 minutes ago | finance.yahoo.comLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCMay 19 at 7:30 AM | businesswire.comLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 15, 2026 | businesswire.comInsider Buying: Lantern Pharma (NASDAQ:LTRN) Director Acquires 48,544 Shares of StockMay 15, 2026 | insidertrades.comLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorMay 14, 2026 | finance.yahoo.comLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorMay 13, 2026 | businesswire.comLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026May 11, 2026 | businesswire.comLantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery TranscriptApril 30, 2026 | seekingalpha.comLantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery TranscriptApril 30, 2026 | seekingalpha.comLantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization ...April 29, 2026 | finance.yahoo.comLantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers GloballyApril 29, 2026 | businesswire.comCORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai – A Platform to Conquer Rare CancersApril 26, 2026 | usatoday.comJoin Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai – A Platform to Conquer Rare CancersApril 24, 2026 | usatoday.comLantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutApril 24, 2026 | businesswire.comEmerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted ...April 21, 2026 | finance.yahoo.comEmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityApril 20, 2026 | businesswire.comLantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut ...April 14, 2026 | finance.yahoo.comLantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22April 14, 2026 | businesswire.comLantern Pharma Showcases withZeta.ai Platform for Rare CancersApril 10, 2026 | tipranks.comLantern Pharma Inc. (LTRN) Shareholder/Analyst Call TranscriptApril 9, 2026 | seekingalpha.comLake Street Reaffirms Their Buy Rating on Lantern Pharma (LTRN)April 5, 2026 | theglobeandmail.comLantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...April 3, 2026 | finance.yahoo.comLantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026April 2, 2026 | businesswire.comLantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks TranscriptMarch 30, 2026 | seekingalpha.comLantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 30, 2026 | businesswire.comLTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drugMarch 27, 2026 | msn.comLantern Pharma (LTRN) price target increased by 25.00% to 25.50March 27, 2026 | msn.comLantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party ReportMarch 27, 2026 | businesswire.comLantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001March 27, 2026 | financialpost.comFLantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001March 27, 2026 | businesswire.comLantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETMarch 23, 2026 | businesswire.comLantern Pharma (LTRN) advances oncology AI and gains orphan drug recognitionFebruary 13, 2026 | msn.comLantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026February 10, 2026 | businesswire.comLantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue SarcomasJanuary 20, 2026 | finance.yahoo.comLantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue SarcomasJanuary 20, 2026 | businesswire.comLantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma ...January 12, 2026 | finance.yahoo.comLake Street Remains a Buy on Lantern Pharma (LTRN)December 23, 2025 | theglobeandmail.comLantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid TumorsDecember 4, 2025 | theglobeandmail.comLantern Pharma announces LP-184 clinical trial met all primary endpointsDecember 3, 2025 | msn.comLantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 TrialsDecember 3, 2025 | businesswire.comLantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors TranscriptNovember 20, 2025 | seekingalpha.comLantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash WiselyNovember 15, 2025 | finance.yahoo.comLantern Pharma’s Q3 2025: Clinical and AI ProgressNovember 14, 2025 | msn.comLantern Pharma Inc. (LTRN) Q3 2025 Earnings Call TranscriptNovember 13, 2025 | seekingalpha.comLantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 13, 2025 | tmcnet.comLantern Pharma to Spotlight AI Drug-Development Platforms at UNT’s First AI4BM SymposiumNovember 13, 2025 | msn.comLantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ETNovember 6, 2025 | businesswire.comLantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNTOctober 30, 2025 | finance.yahoo.comLantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in ...October 28, 2025 | finance.yahoo.comLantern Pharma presents clinical data from LP-284October 28, 2025 | msn.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼1.260.40▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼72▲LTRN Articles Average Week Get the Latest News and Ratings for LTRN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lantern Pharma and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NRXP News ATYR News FTLF News QTTB News BTMD News ETHZ News ANVS News ACRV News CTOR News GOSS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
